Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
New England Journal of Medicine · 23.02.2023 · 388 (8) · 694-705
DOI: 10.1056/nejmoa2211075 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.02.2023. Verfasst von Johnny Mahlangu und 29 weiteren Autor:innen. Beteiligte Einrichtung: From the Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, and National Health …. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 209-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: BioMarin Pharmaceutical.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, and National Health Laboratory Service, Johannesburg (J. Mahlangu); the Department of Pedi…
ORCID-Profile: Margareth C Ozelo, Flora Peyvandi
Förderung
- BioMarin Pharmaceutical
Zitieren
APA
Mahlangu, J., Kaczmarek, R., von Drygalski, A., Shapiro, S., Chou, S. C., Ozelo, M. C., Kenet, G., Peyvandi, F., Wang, M., Madan, B., Key, N. S., Laffan, M., Dunn, A. L., Mason, J., Quon, D. V., Symington, E., Leavitt, A. D., Oldenburg, J., Chambost, H., …, & GENEr8-1 Trial Group (2023). Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. New England Journal of Medicine, 388(8), 694-705. https://doi.org/10.1056/nejmoa2211075
Vancouver
Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. New England Journal of Medicine. 2023;388(8):694-705. doi:10.1056/nejmoa2211075
BibTeX
@article{Mahlangu2023,
author = {Mahlangu, Johnny and Kaczmarek, Radoslaw and von Drygalski, Annette and Shapiro, Susan and Chou, Sheng-Chieh and Ozelo, Margareth C and Kenet, Gili and Peyvandi, Flora and Wang, Michael and Madan, Bella and Key, Nigel S and Laffan, Michael and Dunn, Amy L and Mason, Jane and Quon, Doris V and Symington, Emily and Leavitt, Andrew D and Oldenburg, Johannes and Chambost, Hervé and Reding, Mark T and Jayaram, Kala and Yu, Hua and Mahajan, Reena and Chavele, Konstantia-Maria and Reddy, Divya B and Henshaw, Joshua and Robinson, Tara M and Wong, Wing Yen and Pipe, Steven W and GENEr8-1 Trial Group, GENEr8-1 Trial Group},
title = {Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {8},
pages = {694--705},
doi = {10.1056/nejmoa2211075}
}
EUVIMED